Yuhan Corporation Secures $30M Milestone from Janssen as Third-Gen EGFR Inhibitor Lazertinib Launches in Europe, Bringing Total Milestones to $150M

May 28, 2026 13:05 CST Updated 13:05

YUHAN

Pharmaceutical Manufacturer

Johnson & Johnson

Medical Device R&D and Manufacturer

Gilead Sciences

Antiviral Drug Developer

Note:This article does not constitute any investment advice or recommendations; please refer to official/company announcements for the final version;This article is intended solely for informational purposes regarding healthcare-related medications. It does not constitute a recommendation for treatment plans (if mentioned) and does not represent the official position of the platform.Authorization is required for the reproduction of any article.

Pharnhub DataMonitoring shows: 2026In mid-May, South Korea's Yuhan releasedIn an announcement, with its third-generation EGFR lung cancer drugLazertinib/Lazcluze inEuropeanOfficially commercially launched, the Company will receive payment from Johnson & Johnson/Janssen BiotechUS$30 million milestone payment。

In 2024, after this therapeutic drug was launched and marketed in the United States, Yuhan secureda $60 million payment; last year, it successively received milestone payments of $15 million triggered by the Japanese market and $45 million from the Chinese market.。(Several major markets have cumulatively achieved USD 150 million in market approval milestones)

On May 20, 2026, U.S.-based Gilead Sciences expanded its collaboration with South Korean integrated pharmaceutical company Yuhan, with both parties entering into an active pharmaceutical ingredient (API) supply agreement valued at KRW 210 billion (approximately USD 140 million). Specific details regarding the supplied products were not disclosed.

The agreement remains valid through the end of 2027, with relevant information disclosed this week via a regulatory announcement (in Korean) on the Korea Exchange (KRX).

The transaction value accounts for 9.6% of Yuhan's 2025 revenue. Yuhan operates two API manufacturing facilities in South Korea and is experiencing rapid business growth, with its overseas sales in the first quarter of 2026 increasing by 21% year-on-year.

Gilead and Yuhan have previously engaged in multiple API CDMO collaborations.

Yuhan Corporation (000100.KS): A well-established South Korean pharmaceutical company (founded in 1926), with business operations coveringInnovative Drug R&D, Generic Drugs, API/CDMOThree major business segments; 2025 revenue approximately2.19 trillion Korean won, with Yuhan Chemical as its core API/CDMO subsidiary.

Early-stage pipeline: Autoimmune IgE Fc fusion protein / MASH GLP-1/FGF21 dual agonist / Rare disease GCS inhibitor are in development.

References:

PharmaCircle Data;

https://www.sec.gov/Archives/edgar/data；

pharma.bcpmdata.com；

http://www.marketscreener.com；

https://www.businesswire.com；

www1.hkexnews.hk/；

https://biz.chosun.com/en/en-science；

https://www.koreabiomed.com/news/articleView.html?idxno=31656；

Wait.